IART
INTEGRA LIFESCIENCES HOLDINGS CORP
Overview
Integra LifeSciences manufactures and sells medical devices and regenerative tissue products in two segments: Codman Specialty Surgical (70% of revenue), which provides neurosurgery, neurocritical care, and ENT technologies and surgical instruments; and Tissue Technologies (30% of revenue), which offers wound reconstruction and regenerative products for burns, chronic wounds, and surgical repair.
INTEGRA LIFESCIENCES HOLDINGS CORP is a Healthcare company operating in Medical Devices with a $1.37B market cap.
Most recent reported earnings: Q2 FY2026 (Jul 29, 2026).
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-05-0516 Q&A exchanges
- Q4 FY2025Earnings2026-02-267 Q&A exchanges
- Q3 FY2025Earnings2025-10-3012 Q&A exchanges
- Q2 FY2025Earnings2025-08-0111 Q&A exchanges
- Q1 FY2025Earnings2025-05-0523 Q&A exchanges
- Q4 FY2024Earnings2025-02-2526 Q&A exchanges
- Q3 FY2024Earnings2024-11-0428 Q&A exchanges
- Q2 FY2024Earnings2024-07-2939 Q&A exchanges
- Q1 FY2024Earnings2024-05-0626 Q&A exchanges
- Q4 FY2023Earnings2024-02-2834 Q&A exchanges
- Q3 FY2023Earnings2023-10-2537 Q&A exchanges
- Q2 FY2023Earnings2023-07-2726 Q&A exchanges
- Q1 FY2023Earnings2023-04-2629 Q&A exchanges
- Q4 FY2022Earnings2023-02-2231 Q&A exchanges
- Q3 FY2022Earnings2022-10-2626 Q&A exchanges
- Q2 FY2022Earnings2022-07-2729 Q&A exchanges
- Q1 FY2022Earnings2022-04-2722 Q&A exchanges
- Q4 FY2021Earnings2022-02-2335 Q&A exchanges
- Q3 FY2021Earnings2021-11-0235 Q&A exchanges
- Q2 FY2021Earnings2021-07-2823 Q&A exchanges
- Q1 FY2021Earnings2021-04-2835 Q&A exchanges
History
Earnings history
- Q2 FY20262026-07-29EPS— vs $0.48—Rev— vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-07-29 | — | $0.48 | — | — | — | — | EODHD |
Source: EODHD. IART reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks IART's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Misses consensus 10/10 quarters
SampleRepeated misses without a guidance reset suggest management is structurally optimistic relative to operating reality. Track whether next-quarter guidance is being benchmarked off the prior miss or the prior plan.
Missed in 4 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $3.52 | $4.35 | -19.1% | +0.3% | -2.3% |
| Q4 FY2026 | $3.65 | $4.38 | -16.7% | -3.7% | -3.1% |
| Q3 FY2026 | $3.31 | $4.20 | -21.3% | -6.7% | -5.5% |
| Q2 FY2026 | $3.60 | $4.20 | -14.2% | +1.7% | +0.6% |
| Q1 FY2025 | $4.02 | $4.26 | -5.6% | -3.9% | -5.0% |
| Q4 FY2025 | $3.85 | $4.25 | -9.4% | -2.8% | -5.4% |
| Q3 FY2025 | $3.50 | $4.40 | -20.4% | -6.7% | -7.3% |
| Q2 FY2025 | $3.76 | $4.29 | -12.4% | -5.8% | -6.0% |
| Q1 FY2024 | $4.00 | $4.52 | -11.4% | -5.0% | -5.8% |
| Q4 FY2024 | $3.52 | $4.36 | -19.2% | +2.6% | +2.2% |
Guidance change history
Sample- Q1 FY2026Lowered2026-04-15
- Q4 FY2026Lowered2026-13-15
- Q3 FY2026Lowered2026-10-15
- Q2 FY2026Lowered2026-07-15
- Q1 FY2025Lowered2025-04-15
- Q4 FY2025Lowered2025-13-15
- Q3 FY2025Lowered2025-10-15
- Q2 FY2025Lowered2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Mojdeh PoulCEO1 yr 5 mo5 callsCurrentSample
CEO since 2025 • 2/4 beats (50%) • last guidance cut Q3 FY2026
- Lea Daniels KnightCFO11 mo2 callsCurrentSample
CFO since 2025 • 2/4 beats (50%) • last guidance raise Q3 FY2026
- Harvinder SinghPresident1 yr 3 mono recorded callsCurrentSample
PRESIDENT since 2025 • 3/4 beats (75%) • last call held guidance Q1 FY2026
- Michael J McBreenPresident1 yr 3 mono recorded callsCurrentSample
PRESIDENT since 2025 • 3/4 beats (75%) • last guidance cut Q1 FY2026
- Robert T Davis JrPresident1 yr 3 mono recorded callsCurrentSample
PRESIDENT since 2025 • 3/4 beats (75%) • last call held guidance Q2 FY2026
- Michael Damon HutchinsonEVP, Chief Legal Officer & Sec5 mono recorded callsCurrentSample
OTHER_C_SUITE since 2026 • 1/2 beats (50%) • last call held guidance Q1 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for IART.
$ curl https://api.spokenalpha.com/v1/companies/IARTFAQ
Frequently asked about IART
Where can I find INTEGRA LIFESCIENCES HOLDINGS CORP's (IART) earnings call transcripts?
Spoken Alpha indexes IART's earnings call transcripts at https://spokenalpha.com/companies/IART. Each call links to attributed speakers and parsed analyst Q&A. INTEGRA LIFESCIENCES HOLDINGS CORP's own investor relations page is at https://investor.integralife.com/.
When was INTEGRA LIFESCIENCES HOLDINGS CORP's most recent earnings call?
INTEGRA LIFESCIENCES HOLDINGS CORP (IART) held its most recent earnings call on 2026-05-05, covering fiscal Q1 2026.
What sector is IART in?
INTEGRA LIFESCIENCES HOLDINGS CORP (IART) operates in the Healthcare sector (Medical Devices industry).